Hepatitis B Virus Reactivation Potentiated by Biologics

Eiichi Ogawa, Mike T. Wei, Mindie H. Nguyen

研究成果: Contribution to journalReview article

抜粋

Hepatitis B virus (HBV) reactivation can be a serious complication for patients with chronic or resolved HBV infection when treated with biologics. For HBsAg-positive patients receiving biologics, the risk of HBV reactivation is moderate to high. HBsAg-negative/anti-HBc positive patients are at lower risk of HBV reactivation than HBsAg-positive patients. However, patients taking anti-CD20 agents, such as rituximab, have high risk of HBV reactivation (>10%), so antiviral prophylactic therapies are required. This review provides the different classes of biologics associated with HBV reactivation, stratifies the various reactivation risk levels by HBV status and biologic agent, and discusses management strategies.

元の言語英語
ページ(範囲)341-358
ページ数18
ジャーナルInfectious Disease Clinics of North America
34
発行部数2
DOI
出版物ステータス出版済み - 6 2020

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

フィンガープリント Hepatitis B Virus Reactivation Potentiated by Biologics' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用